- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03929783
Recruitment Status Recruiting
First Posted April 29, 2019
Last update posted February 23, 2021
This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, may help to reclassify findings seen on diagnostic mammography and ultrasound as benign or likely benign with what would otherwise require biopsy for confirmation.
PRIMARY OBJECTIVES: I. To obtain preliminary data to support the hypothesis that contrast enhanced mammography (CEM) can reduce benign tissue diagnosis (FP3) and therefore improve positive predictive value 3 (PPV3). SECONDARY OBJECTIVES: I. Identify specific CEM characteristics that accurately classify a finding as benign, high-risk or malignant. II. Assess the positive and negative predictive values for each digital breast tomosynthesis (DBT), breast ultrasound and CEM. EXPLORATORY OBJECTIVES: I. To compare the outcomes/endpoints stratified by age to determine if age affects the ability of CEM to accurately define a lesion as benign, probably benign or suspicious. OUTLINE: Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day or up to 3 days later.
|Experimental: Diagnostic (CEM)
Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
Procedure: Contrast Enhanced Digital Mammography
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Women with digital breast tomosynthesis and/or ultrasound assessments of Breast
Imaging Reporting and Data System (BI-RADS) 4 and 5 lesions with recommendation of
needle biopsy for tissue diagnosis.
- Abnormal findings include masses, focal, global or developing asymmetries,
architecture distortions, or > 1 cm of suspicious calcifications with or without
associated ultrasound abnormal findings.
- Scheduled for imaging guided percutaneous needle biopsy.
- Provide signed and dated informed consent form.
- If patient is of childbearing potential, a negative pregnancy test, urine or blood,
within 14 days prior to the scan.
- < 1 cm span of calcifications without an ultrasound correlate. - Pregnant patients. - Patients with known allergy to iodinated contrast material. - If patient answers YES to any of the below questions they need glomerular filtration rate (gFR) prior to contrast administration regardless of their age: - Have you ever been told you have renal problems? - Have you ever been told you have protein in your urine? - Do you have high blood pressure? - Do you have diabetes? - Do you have gout? - Have you ever had kidney surgery?
Contact: Lydai Liao 215-955-5412 email@example.com
United States, Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University
Thomas Jefferson University
Principal Investigator: Lydia Liao Sidney Kimmel Cancer Center at Thomas Jefferson University